Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age0-52
SponsorUniversity of Utah

About this trial

Determine 1) the impact of abnormal fetal cerebrovascular physiology with neurodevelopmental delay (ND) outcomes and 2) how this relationship is modified by patient and environmental factors such as chronic congenital heart disease (CCHD) lesion, maternal-fetal environment, and social determinants of heath (SDOH) in a diverse population using a multicenter design.

Pregnant women will be approached during one of their fetal cardiology clinic visits.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pregnant women 18 years of age and over with a singleton fetus with known or suspected congenital heart disease anticipated to need intervention or surgery within 30 days of birth.

Disqualifiers

Known fetal chromosomal or genetic abnormalities

Multiple gestation pregnancy

Fetal extra-cardiac anomalies

Trial design

Design model

Single group

Treatments tested in this trial

  • Single Arm

    Procedure/Surgery

    * Phase 1- Baseline: A fetal echocardiogram will be performed as part of routine standard clinical care. * Phase 2- MH: The participant will be placed on 8 litres of 100% FiO2 (inspired oxygen fraction) via a non-rebreather face mask for 10 minutes. After 10 minutes, additional images will be obtained. MH will be discontinued after additional imaging is complete. * Phase 3- Recovery: After at least 5 minutes of discontinuation of MH, additional images will be obtained to ensure any changes have returned back to baseline.

  • Neonatal Neurobehavioral Scale

    Procedure/Surgery

    Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) evaluation: All neonates with CHD expected to undergo neonatal cardiac intervention or surgery have pre-operative NNNS assessment as PCH as standard of care. The NNNS takes approximately 30 minutes to complete. It is administered by a licensed physical, speech, or occupational therapist who has completed training and additional certification. The NNNS therapist will be blinded to the results of the fetal echocardiogram and MCA-PI.

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: Single ArmExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Pre-operative Neonatal Network Neurobehavioral Scale (NNNS) attention scores

The NeoNatal Neurobehavioral Scale (NNNS-II) examines the neurobehavioral organization, neurological reflexes, motor development - active and passive tone, and signs of stress and withdrawal of the at-risk and drug-exposed infant

Time frame
<=30 days of life
2

Baseline MCA-PI and change in MCA-PI with Maternal Hyperoxia

The fetal middle cerebral artery (MCA) pulsatility index (PI)

Time frame
<= 30 days of life

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Utah

Lead sponsor

Primary Children's Hospital

Collaborator

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator